A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CDX-6114 Following Single, Ascending Oral Dose Administration to Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2018
Price : $35 *
At a glance
- Drugs CDX-6114 (Primary)
- Indications Phenylketonuria
- Focus Adverse reactions; First in man
- Sponsors Codexis
- 08 Nov 2018 Results presented in a Codexis Media Release
- 08 Nov 2018 According to a Codexis media release, all of the defined endpoints were met.
- 18 Sep 2018 Status changed from active, no longer recruiting to completed.